10.03.2025
Publications category: MIDD
03.03.2025
Model-informed drug development of flucytosine sustained release formulation in the treatment of cryptococcal meningitis: A case study using PBPK modeling
11.02.2025
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
20.11.2024
Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
11.11.2024
Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study
11.11.2024
Phase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEK
11.11.2024
A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
05.11.2024
A workflow for comparing drug candidates based on Probability of Pharmacological Success (PoPS)
25.06.2024
A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis D
25.06.2024
Optimal design of a reduced sampling schedule for the characterization of prolactin dynamics in healthy male volunteers and its evaluation to the describe the pharmacodynamic effect of a prolactin antagonist in a single rising dose study
25.06.2024